The Proposal at a Glance — Published August 21, Comments Due October 21
On August 21, 2026, Korea's Ministry of Food and Drug Safety (MFDS) issued a proposed partial amendment to the Enforcement Rule on the Safety of Pharmaceuticals, Etc. Public comments are due by October 21. The rule is not yet final or in force, and details may change during consultation and regulatory review. Everything below is based on the published proposal.
The amendment is part of MFDS's "60 Food and Drug Safety Tasks" agenda. It puts into regulation the plan to shorten clinical trial approval times that MFDS announced in early July. It is also a separate measure from the already announced 240-day new drug review target. That target covers marketing authorization, while this amendment covers the earlier step of getting into the clinic.
Key Change 1 — IND Review Cut from 30 Days to 10
The main change reduces the processing time for clinical trial application (IND) approvals — including amendment approvals — from 30 days to 10. It comes with a condition: the pre-review must find the application adequate. Not every IND will get a 10-day decision automatically.
Your data package has to be ready earlier. To pass pre-review, nonclinical toxicology and pharmacology data and CMC (chemistry, manufacturing and controls) data need to be essentially complete before you file. That means moving CRO report delivery and investigational product manufacturing earlier in the schedule.Plan conservatively. When you give investors a first-patient-in (FPI) date, base it on the 30-day timeline and show 10 days separately as an upside scenario. A single request for additional data can wipe out the 20 days you saved.Milestone impact. If you enter the clinic about three weeks earlier, you can also reach the data points that anchor your next financing round or licensing talks sooner.Key Change 2 — Minor Changes Such as Address Updates Move to Notification
Under this amendment, the change that moves from approval to notification is an address change caused by administrative redistricting. For context, the rule letting some non-CMC protocol amendments be reported rather than approved was introduced by a 2020 Prime Ministerial Decree amendment and is already in force — it is not new in this proposal.
Check what actually qualifies. Whether adding a trial site or editing a protocol needs approval or only notification is determined by the existing list of reportable changes in the MFDS regulation on clinical trial plan approval — this amendment does not add to that list.Accountability doesn't go away. Even under notification, you are still responsible for keeping records of the rationale, supporting documents and IRB approvals. Update your change-control SOP so you are ready for post-hoc inspections.Other Procedural Simplifications
Address changes due to administrative redistricting. Manufacturers, importers and contract-manufacturing marketers will be able to report these within one year. Clinical trial plans will also move from amendment approval to notification for these changes.Bioanalytical and nonclinical testing facilities. Changes to a facility's address or representative will shift from re-designation to notification. If your CRO or lab contracts require notice "upon change of designation," consider revising the wording to "upon notification."Roadmap for Bio SMEs
Now (comment period through October 21): Identify issues that affect your pipeline, such as the criteria for an "adequate" pre-review finding or the scope of quality changes, and submit comments through industry associations.Before the rule takes effect: Draft a plan for using pre-review, an approval-vs-notification classification table for amendment types, and a revised change-control SOP.After the rule takes effect: Rebuild your clinical timelines and funding plans around the shorter review period, and align them with application windows for government clinical-stage R&D programs.How KITIM Can Help
KITIM supports bio SMEs through the entire path into the clinic. That includes reviewing IND pre-review packages, classifying amendments as approval or notification, updating change-control SOPs, and planning government R&D projects for the clinical stage. If you'd like to understand how this proposal affects your pipeline timeline, please contact KITIM through our inquiry page to schedule a consultation.
